Edition:
United States

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

3.40USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.40
Open
$3.45
Day's High
$3.50
Day's Low
$3.40
Volume
17,303
Avg. Vol
25,940
52-wk High
$6.85
52-wk Low
$2.78

Chart for

About

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates... (more)

Overall

Beta: 0.42
Market Cap(Mil.): $111.51
Shares Outstanding(Mil.): 31.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

Jan 08 2018

BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa

* PROQR RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR DRUG CANDIDATE QR-313 FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Proqr reports loss of EUR 0.42 per share​

* Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​ Source text for Eikon: Further company coverage:

Nov 20 2017

BRIEF-ProQR doses first LCA 10 patient in clinical trial of QR-110

* ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness

Nov 13 2017

BRIEF-JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14

* JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​ Source text: (http://bit.ly/2yhtqSA) Further company coverage:

Oct 11 2017

BRIEF-ProQR announces positive top-line results from a phase 1b study of QR-010

* ProQR announces positive top-line results from a Phase 1b study of QR-010 in subjects with Cystic Fibrosis

Sep 25 2017

BRIEF-ProQR gets orphan drug designation from FDA for drug candidate QR-313

* ProQR receives orphan drug designation from FDA for drug candidate QR-313 for dystrophic epidermolysis bullosa and will present data at two scientific conferences

Sep 19 2017

BRIEF-ProQR Therapeutics spins out Amylon Therapeutics

* ProQR therapeutics - spun out Amylon Therapeutics, a privately-held company focused on development of therapies for central nervous system disorders

Sep 12 2017

Earnings vs. Estimates